Background: Monthly intramuscular Palivizumab (Synagis, MedImmune, Inc.) is effective in reducing the incidence of RSV-attributable hospitalization by 55% if compared with placebo and seems to be well tolerated.
Methods: Our clinical experience in the use of palivizumab in RSV-prophylaxis is presented. During autumn-winter 1999-2000, a total of 8 newborns (gestational age between 28-34 weeks) in our neonatal intensive care unit (NICU) met the AAP recommendations for RSV-immunoprophylaxis. Palivizumab was monthly administered at a dosage of 15 mg/kg i.m. at discharge from the NICU and during the RSV season. Infants were followed up to 40 days from the last injection for adverse reactions and clinical data.
Results: Among eligible newborns, two (28 and 29 weeks respectively) were affected by CLD and required medical therapy at discharge, 4 were born at 29-32 weeks and 2 (both of them born at 34 weeks) had additional risk factors of infection (crowded environment, passive smoking). During RSV season, none of the infants experienced RSV-hospitalization nor lower respiratory tract infection. Mild and transient adverse effects occurred in 2 cases out of 8 (induration in the site of injection and irritability).
Conclusions: In our series of patients, palivizumab resulted safe and effective.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acute respiratory infections (ARIs) are a leading cause of death in children under five globally. The seasonal trends and profiles of respiratory viruses vary by region and season. Due to limited information and the population's vulnerability, we conducted the hospital-based surveillance of respiratory viruses in Eastern Uttar Pradesh.
View Article and Find Full Text PDFCharacteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine.
Medicina (Kaunas)
January 2025
Department of Health Sciences, University of Genoa, 16132 Genoa, Italy.
: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of the first vaccine-takers can pave the way for a successful vaccination campaign. The objective of this study was to explore the sociodemographic and clinical characteristics of the first Italian users of an adjuvanted RSV vaccine and their attitudes towards RSV and vaccination.
View Article and Find Full Text PDFCirculation of Respiratory Syncytial Virus (RSV) in Poland Between Seasons of 2009/2010 and 2022/2023 Based on SENTINEL System.
Microorganisms
January 2025
Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
Respiratory Syncytial Virus (RSV) is a prevalent pathogen of the respiratory tract, posing a significant threat to individuals with compromised immune systems, particularly the elderly and neonates in hospital settings. The primary objective of this study was to identify a specific period within the epidemic season during which healthcare providers can anticipate an increased incidence of RSV infections and characterize the epidemic season in Poland. Molecular biology techniques were employed to diagnose samples at Sanitary Stations and the National Institute of Public Health (NIC) in Warsaw.
View Article and Find Full Text PDFRespiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
Lancet Infect Dis
January 2025
Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA, USA.
Background: New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information on the real-world effectiveness of these vaccines is needed.
Methods: We used electronic health records in the Veterans Health Administration to emulate a target trial comparing a single dose of a recombinant stabilised prefusion F protein RSV vaccine versus no vaccination among veterans aged 60 years and older.
ANALYSIS OF PUBLIC INTEREST ABOUT OSTEOPOROSIS USING GOOGLE TRENDS: ARE SEASON AND ECONOMY EFFECTIVE?
Acta Endocrinol (Buchar)
January 2025
Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey.
Background: The aim of this study was to assess the awareness of the USA and world population about osteoporosis, taking into account seasonal variations and economic conditions.
Methods: The term "osteoporosis" was searched using Google Trends between January 1, 2004 and September 12, 2024. Cosinor analysis was used to test the effect of seasonality on relative search volumes (RSV) for osteoporosis searches in the USA and worldwide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!